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mary endpoint of target vessel revascularization (TVR) was reached in 63 (13.9%)
patients. Several polymorphisms seem to play a role in the restenotic process. So far we
identified an association between interleukin 4 (p=0.026) and three polymorphisms in the
adrenergic beta-2 receptor (p=0.064,0.011,0.077) and TVR. Also cytotoxic T-lymphocyte-
associated protein 4 seems to be associated with TVR (p=0.032) More genotyping is
being performed at this moment.
Conclusion: Several polymorphisms seem to play a role in the restenotic process in
patients with diabetes mellitus. Interleukin 4, cytotoxic T-lymphocyte-associated protein 4
and adrenergic beta-2 receptor seem to be three important genes in the process of rest-
enosis in diabetics. This can lead to a better risk stratification and to a more tailored ther-
apy for diabetic patients to prevent restenosis after PTCA.
1103-196 Circulating Endothelial Progenitor Cells in Patients With 
Unstable Angina: Association With Systemic 
Inflammation
Hylton I. Miller, Jacob George, Emil Goldstein, Sulico Abshizada, Arik Finkelstein, Itzhak 
Herz, Gad Keren, Tel-Aviv Medical Center, Tel-Aviv, Israel
Background: Endothelial progenitor cells (EPC) are present in the peripheral circulation
and can develop a functional endothelial phenotype. Number and function of circulating
EPC is altered in atherosclerosis, diabetes and after myocardial infarction. We studied
the number (num) and adhesive properties of EPC from patients (pts) with unstable-
angina and no evidence of cardiac necrosis.
Methods: Pts with either unstable-angina (UA) (n=29) and no cardiac necrosis, and pts
with stable-angina (SA) (n=12) with similar atherosclerotic risk factors, medication use,
and coronary vessel disease. The number of circulating EPC was determined by colony-
forming unit assay and their adhesive properties were determined by their capacity to
bind immobilized-fibronectin. High-sensitivity C-reactive protein (CRP) was determined in
all pts.
Results: Circulating EPC were significantly increased in patients with UA as compared
with SA (24.5±2.6 versus 13.3±2.9). 7 pts with UA followed for 3 months after clinical sta-
bilization exhibited a near 50% reduction in num of circulating EPC. Adhesive capacity of
EPC from UA and SA did not differ. A positive correlation was found between systemic
CRP levels and circulating EPC num but not with their adhesive capacity.
Conclusion: Pts with UA and no evidence of cardiac necrosis exhibit increased circulat-
ing EPC. System inflammation, in addition to recognized growth factors, could play a role
in peripheral mobilization of EPC in patients with anginal-syndromes. 
1103-197 Chlamydia Pneumoniae-Heat Shock Protein 60 Induces 
a Highly Specific Persistent Immune Response in 
Patients With Unstable Angina Independently From IgG 
and IgA Seropositivity
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Monaco, Gaetano Lanza, Antonio Rebuzzi, Germano Melissano, Roberto Chiesa, Filippo 
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Background: The humoral response against Chlamydia Pneumoniae (CP)-HSP60, an
highly immunogenic molecule with high degree of sequence homology with the human
HSP60, was found to be highly specific for acute coronary syndromes.
Methods: Among 984 patients with unstable angina (UA) included in the SPAI (Stratifi-
cazione Prognostica Angina Instabile) Study, we selected 119 subjects with unfavourable
and 119 with good outcome (as combined end point: death, myocardial infarction and
readmission for UA within 180 days after admission) matched for age, gender, risk factors
and clinical presentation. As stable atherosclerotic controls (PVD) we assessed 66
patients scheduled for carotid endarterectomy without evidence of coronary disease
(excluded by dobutamine stress echocardiography). In all patients we analized Cp-
HSP60 IgG, measured by an in-house ELISA, Cp-IgG and CP-IgA levels, measured by a
commercially available microimmunofluorescence assay (Labsystems), with titers > 1:32
regarded as positive. In UA population we also assessed the time course of seropositivity
(defined as an ELISA reading of > 0.30) at discharge and at 90 days.
Results: In UA, IgG and IgA CP-seropositivity was only found in 58% (vs PVD 80.3%
p<0.01) and 21% (vs PVD 30.3%; ns) respectively, but all UA patients on admission were
positive (100%) for antibodies against CP-HSP60, conversely only 12% of PVD were
positive for antibodies against CP-HSP60.
In UA CP-HSP60 antibody titers on admission were not correlated to clinical presenta-
tion, outcome, C-reactive protein or Troponin I levels.
In UA, CP-HSP60 antibody titers increased significantly at 90 days [median (range);
admission 0.50 (0.3-1.0) vs discharge 0.60 (0.3-1.3) respectively; p < 0.01].
Finally, CP-HSP60 titers in UA were higher in CP-seropositive than seronegative
patients, while no difference was observed in PVD.
Conclusion: Seropositivity to CP-HSP60 is highly specific for UA and increases signifi-
cantly up to 90 days, despite stability of IgG and IgA antibody titres against CP, most
likely suggesting an antigenic mimicry.
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1104-189 Enhancement of Bone Marrow-Derived Endothelial 
Progenitor Cell Differentiation by Protease-Activated 
Receptor-1 Activation
Sima T. Tarzami, Guoming Wang, Lisa Green, JaiPal Singh, Eli Lilly and Company, 
Indianapolis, IN
Background: Recent advances in stem cell research have revealed that endothelial pro-
genitor cells (EPCs) from bone marrow play important role in angiogenesis in response
to injury and ischemia. The specific mediators involved in the mobilization, recruitment,
differentiation and incorporation of EPCs into the blood vessels are not understood.
Since coagulation factors play important role in injury response and angiogenesis, we
have investigated the role of protease-activated receptor (PAR) in EPC differentiation and
proliferation.
Methods: Mouse bone marrow cells were isolated and plated on fibronectin-coated
dishes for 10-14 days. Later, adherent cells were treated with thrombin or the indicated
agent for 4 days and then analyzed by fluorescence activated cell sorter (FACS). FACS
analysis was performed to determine the effect of thrombin on other progenitor cell mark-
ers such as CD34, c-kit, AC133 and VE-cadherin. Cell prolifiration was assayed by mea-
suring DNA synthesis and it was determined by measurement of 3[H] thymidine uptake.
Cells morphology was examined using confocal microspy.
Results: Treatment of CD34+ cells with thrombin or PAR-1 activating-peptide produced a
significant increase in the number of VE-cadherin positive cells. Hirudin or a small molec-
ular weight inhibitor of thrombin attenuated the increase in VE-cadherin positive cells.
Blocking the vascular endothelial growth factor (VEGF) receptor 1 or VEGF receptor 2
using neutralizing antibodies did not produce a significant change in EPC differentiation
in response to thrombin.
Conclusion: These result, for the first time, show a direct role of thrombin and PAR-1 in
EPC proliferation and differentiation. These findings also suggest that thrombin may con-
tribute to vascular regeneration by modulating endothelial progenitor cells.
1104-190 Angiogenic Profiling of the Ischemic Human Heart In 
Vivo
Wang Yongzhong, Anders Gabrielsen, Patrick Lawler, Gabrielle Berne Paulsson, Daniel 
Steinbruchel, Goran Hansson, Jens Kastrup, Karolinska Institute, Stockholm, Sweden, 
Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark
Background: At present, the understanding of endogenous expression of factors
involved in angiogenesis in the myocardium is incomplete. Therefore, we performed
Affymetrix® GeneChip analysis on normal and chronic ischemic myocardium before and
during acute ischemia and reperfusion stress in humans.
Methods: Myocardial biopsies were sampled at baseline, after 45 min of acute total
ischemia, and after 30 min of reperfusion recovery from both normally perfused and
chronic reversibly ischemic myocardium in 6 patients undergoing coronary artery by-pass
grafting. RNA was isolated, amplified with established techniques, and hybridized to
HG_U133A Affymetrix® Genechip arrays. A total of 33 arrays were performed, normal-
ized with the RMA algorithm and analyzed for expression patterns of pro- and anti-angio-
genic factors.
Results: Array analysis demonstrated increased baseline expression of VEGF-C and
CYR61 angiogenic inducer in chronic ischemic myocardium compared with healthy tis-
sue. VEGF-A expression did not differ between chronic ischemic and normal myocar-
dium, and was induced in response to ischemia in both tissues. Interestingly, expression
of several potent anti-angiogenic factors, i.e. thrombospondins and endostatin tended to
increase in response to 45 min of acute ischemia in the diseased, ischemic tissue, but
not in normally perfused myocardium. Furthermore, chronic ischemic tissue exhibited a
fibrotic response to acute ischemia and reperfusion (e.g. increased collagen and
fibronectin expression), whereas normal myocardium did not.
Conclusion: These findings suggest that, on a transcriptional level, the balance between
angiogenesis and fibrosis in the myocardium differs between healthy and chronic
ischemic tissue. Although chronic ischemic myocardium expresses pro-angiogenic mole-
cules, this expression seems to be more strongly opposed by expression of anti-angio-
genic factors and super-imposed by a fibrotic response. These features should be kept in
mind when designing therapeutic angiogenic treatment.
